Literature DB >> 16488580

Transporters as a determinant of drug clearance and tissue distribution.

Yoshihisa Shitara1, Toshiharu Horie, Yuichi Sugiyama.   

Abstract

Transporters play an important role in the processes of drug absorption, distribution and excretion. In this review, we have focused on the involvement of transporters in drug excretion in the liver and kidney. The rate of transporter-mediated uptake and efflux determines the rate of renal and hepatobiliary elimination. Transporters are thus important as a determinant of the clearance in the body. Even when drugs ultimately undergo metabolism, their elimination rate is sometimes determined by the uptake rate mediated by transporters. Transporters regulate the pharmacological and/or toxicological effect of drugs because they limit their distribution to tissues responsible for their effect and/or toxicity. For example, the liver-specific distribution of some statins via organic anion transporters helps them to produce their high pharmacological effect. On the other hand, as in the case of metformin taken up by organic cation transporter 1, drug distribution to the tissue(s) may enhance its toxicity. As transporter-mediated uptake is a determinant of the drug elimination rate, drug-drug interactions involving the process of transporter-mediated uptake can occur. In this review, we have introduced some examples and described their mechanisms. More recently, some methods to analyze such transporter-mediated transport have been reported. The estimation of the contributions of transporters to the net clearance of a drug makes it possible to predict the net clearance from data involving drug transport in transporter-expressing cells. Double transfected cells, where both uptake and efflux transporters are expressed on the same polarized cells, are also helpful for the analysis of the rate of transporter-mediated transcellular transport.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16488580     DOI: 10.1016/j.ejps.2005.12.003

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  87 in total

1.  Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.

Authors:  Jackie C Bloomer; Mike Nash; Alison Webb; Bruce E Miller; Aili L Lazaar; Claire Beaumont; William J Guiney
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

2.  Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.

Authors:  Manthena V S Varma; Yurong Lai; Bo Feng; John Litchfield; Theunis C Goosen; Arthur Bergman
Journal:  Pharm Res       Date:  2012-05-26       Impact factor: 4.200

Review 3.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

4.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

5.  Simultaneous absolute quantitation of ATP-binding cassette transporters in normal dog tissues by signature peptide analysis using a LC/MS/MS method.

Authors:  Luke A Wittenburg; Dominique Ramirez; Holly Conger; Daniel L Gustafson
Journal:  Res Vet Sci       Date:  2018-11-12       Impact factor: 2.534

Review 6.  Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.

Authors:  Joseph M Custodio; Chi-Yuan Wu; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2007-11-28       Impact factor: 15.470

7.  Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.

Authors:  Koji Abe; Arlene S Bridges; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-12-15       Impact factor: 3.922

8.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

9.  Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.

Authors:  Varun Khurana; Mukul Minocha; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Metabol Drug Interact       Date:  2014

Review 10.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.